Although pembrolizumab was granted accelerated approval for the first-line treatment of patients with advanced nonsquamous NSCLC in May 2017 without PD-L1 status restriction, we identified increasing use across all strata of PD-L1 expression in the period that preceded this accelerated approval.10 Moreover, first-line ICI therapy increased over time in the subset of patients with advanced squamous NSCLC before the expanded approval for this histologic type in October 2018. This evidence concerns the gene CD274 and non-small cell lung carcinoma.